Latest news with #EliLilly&Company
The Print
4 days ago
- Health
- The Print
Mounjaro, Wegovy signal ashift in obesity care model in India which sees 20k bariatric surgeries a year
Mounjaro, manufactured by US-based Eli Lilly & Company and which has tirzepatide as its active pharmaceutical ingredient (API), was launched in India 20 March. Wegovy, a weight loss drug by Danish drugmaker Novo Nordisk which has semaglutide as its API, hit the Indian markets 25 June. But the development has another fallout that has become a talking point among physicians treating and managing obesity—a possible reduction in the number of bariatric surgeries or weight loss surgery, a series of procedures intended to reshape or alter the anatomy of the stomach to reduce weight. New Delhi: The back-to-back arrival of two high-profile weight loss drugs in India, Mounjaro and Wegovy, over the past four months has fuelled an intense competition in the country's burgeoning anti-obesity market as one megaseller tries to outshine the other. The prescription-only drugs mimic the effects of the natural gut hormones that work by lowering caloric intake, primarily by influencing appetite control mechanisms, and can result in weight of up to 15-20 percent. Many clinicians say this will lead to fewer people opting for bariatric surgeries, which, depending on the extent and type of the surgery, result in a moderate 15 percent to a high of over 50 percent weight loss. 'As Wegovy and Mounjaro are now available for patients struggling with obesity, I see fewer patients opting for bariatric surgeries, especially the simpler procedures which are also more common, as they offer nearly comparable weight loss results,' Dr Naval K. Vikram, a professor of medicine and obesity researcher at the All India Institute of Medical Sciences in New Delhi, told ThePrint. His colleague, a bariatric surgeon at the premium institute who did not want to be named, also said the number of adjustable gastric banding and gastric sleeve surgeries, which are less complex but also result in moderate weight loss, could particularly take a hit. As per statistics shared by the Obesity and Metabolic Surgery of India (OSSI), India has over the past five to seven years consistently performed around 20,000 bariatric surgeries a year. 'While patient hesitation was common in the early years, growing awareness about the broader health benefits of bariatric surgery, along with the introduction of advanced technologies such as robotic-assisted surgery, has encouraged more individuals to consider it,' said Dr Sukhvinder Singh Saggu, the national convener of the OSSI national registry. A last year study examining a large sample of patients with obesity in the US found that the usage of anti-obesity drugs doubled from 2022 to 2023 in the country, and there was a sharp decline (25.6 percent) in the number of patients undergoing metabolic bariatric surgery to treat obesity. Most physicians see the trend getting repeated in India in the coming months. India's anti-obesity drug market is currently valued at Rs 3,000-3,500 crore, and is projected to grow nearly eightfold to Rs 25,000 crore by 2030 as per the market estimates. Also Read: Oil is making India obese and import-hungry. Modi wants to change that Someone's gain, someone's loss Chennai-based diabetologist Dr V. Mohan, an obesity researcher and the chairman of the Madras Diabetes Research Foundation (MDRF), said the advent of new age weight loss drugs marks a paradigm shift in obesity management, similar to what the arrival of drug classes such as proton pump inhibitors (that reduce stomach acid production) meant for the fate of peptic ulcer surgeries. 'At one point, procedures such as gastrojejunostomy for patients of peptic ulcers were very common but these procedures are barely needed now. I see a similar shift in the bariatric surgery landscape and these procedures would increasingly be reserved for people with very high body mass index (BMI),' Mohan said. Bariatric surgery is generally considered for individuals with a Body Mass Index (BMI) of 40 or higher, or for those with a BMI of 35 or higher and serious obesity-related health problems. These health problems can include type 2 diabetes, high blood pressure, or severe sleep apnea. In some cases, surgery may also be an option for individuals with a BMI between 30 and 34 who have poorly controlled type 2 diabetes. But in Indians, where in several people BMI of even nearly 30 can cause a problem due to fat deposition near vital organs, surgery is sometimes indicated. A 2023 survey by the Indian Council of Medical Research (ICMR) and Madras Diabetes Research Foundation (MDRF) had shown that 25.4 crore Indians had generalised obesity. A large number of people have body weight exceeding BMI of over 35 and body weight of even 100 kg and above, say doctors. In such patients, the surgery works by altering the digestive system to reduce food intake and/or absorption, leading to weight loss and improvement of obesity-related health issues. In comparison, Mounjaro and Wegovy primarily influence appetite control mechanisms. In May this year, Lilly said in a statement that a head-to-head clinical trial comparing tirzepatide and semaglutide in their maximum tolerable dosages showed the former to be significantly more effective in reducing both weight and waist circumference after 72 weeks of treatment. According to the U.S. based pharma giant, the participants administered tirzepatide saw an average weight reduction of 20.2 percent, while those on semaglutide experienced a 13.7 percent loss—indicating a 47 percent greater relative weight loss for the former, based on the treatment-regimen estimand at 72 weeks. But some doctors said while tirzepatide is better than semaglutide in percentage of weight loss, there is stronger evidence in case of semaglutide for reducing cardiovascular conditions in obese people without diabetes and also for treating kidney and diabetes. Dr Naval K. Vikram, the AIIMS professor quoted above said, for people who opted for simpler bariatric surgeries, which also meant lesser complications but relatively lower weight loss result, these drugs will be a likelier choice. 'Their cost,' he said, 'however could be a dampener as they are expensive and will need recurring expenses.' The monthly cost of the first three dosing strengths of Wegovy, which are typically the starting dosages, has been kept at Rs 17,345, the last two dose strengths or the maintenance dose cost Rs 24,280 and Rs 26,050 respectively. The starting dose of Maunjaro, on the other hand, costs Rs 14,000 per month while the higher dose costs Rs 17,500 per month. But Mohan countered that surgeries do not come cheap either and generally cost Rs 2 lakh to even more than Rs 6 lakh. 'Plus, these procedures are complicated, cause permanent changes in the stomach structure and sometimes patients tend to regain weight later on for which they need therapeutic intervention,' he said. Step up for obesity management On their part, metabolic and obesity surgeons maintained that these surgeries are no longer seen merely as a weight-loss procedure but widely recognised as a powerful therapeutic tool for managing a range of obesity-related conditions, including type 2 diabetes, coronary artery disease, hypertension, high cholesterol, infertility, and sleep apnea. The integration of robotic systems has further enhanced outcomes by offering greater precision, faster recovery, and improved patient comfort, Dr Sukhvinder Singh Saggu said. Surgeons also insisted that the approach to obesity treatment in India is also evolving into a multimodal strategy, similar to cancer care where surgery, chemotherapy, and radiotherapy work in tandem. 'Given that obesity is a complex, chronic, and multifactorial condition, the treatment now combines weight loss drugs, lifestyle management, exercise, and bariatric surgery, tailored to the patient's BMI and health profile,' Saggu said. 'So we do not see these (anti-obesity medications) as a challenge to bariatric surgery. Instead, these drugs complement surgical options, broadening the spectrum of treatments available,' he also said. Both approaches have their limitations, but together they form part of a comprehensive obesity management pathway designed to deliver sustained health benefits, the OSSI member further said. Dr Parimuthukumar, a senior consultant in minimally invasive gastrointestinal and bariatric surgery at Prashanth Hospitals in Chennai, pointed out that patients are assessed based on their BMI, which categorises them as overweight, obese (Class 1, 2, 3), or even super obese. 'Bariatric surgery is never the first line of treatment. When a patient comes in, we always begin by recommending dietary changes and lifestyle modifications,' he said. Not all patients, however, are able to follow through successfully and in such cases, surgeons may consider weight-loss medications, depending on the patient's suitability. 'Only when both non-invasive options do not yield the desired results, and if the patient meets clinical criteria, do we proceed with bariatric surgery,' Parimuthukumar said, adding that it's a gradual, stepwise approach. 'Whichever method is used — diet, drugs, or surgery — weight loss happens over time, not overnight. But ultimately, reaching a healthier weight improves patients' physical mobility and often reduces their dependence on medication,' he said. (Edited by Ajeet Tiwari) Also Read: Obesity care in India is evolving—no longer just diets & surgery, it's all about multi-specialty approach
Yahoo
24-06-2025
- Business
- Yahoo
Eli Lilly (LLY) Retains $1,100 Price Target at Bernstein Ahead of Diabetes Conference
Eli Lilly & Company (NYSE:LLY) is one of billionaire Stan Druckenmiller's top stock picks with huge upside potential. Bernstein SocGen Group reaffirmed its Outperform rating and $1,100 price target for Eli Lilly & Company (NYSE:LLY) on June 13 ahead of the 85th Annual Meeting of the American Diabetes Association. Pixabay/Public Domain The firm outlined a number of crucial data presentations that Eli Lilly & Company (NYSE:LLY) is expected to provide at the next meeting. One of these is the full description of the ACHIEVE-1 study, which is the first phase 3 trial from the late-stage clinical program of orforglipron. Bernstein is especially keen to acquire more information on the negative event profile and discontinuation rates, even if topline data is already available. Additionally, Eli Lilly & Company (NYSE:LLY) will provide information about its muscle-wasting medication, bimagrumab. When paired with tirzepatide, this will be the first clinical data reported for an anti-muscle wasting agent used in conjunction with a GLP-1 receptor agonist, possibly hinting at future use cases. Eli Lilly & Company (NYSE:LLY) is a major global pharmaceutical company that develops, manufactures, and distributes a wide range of drugs. Founded in 1876, it has grown to become one of the world's largest pharmaceutical companies. While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Connectez-vous pour accéder à votre portefeuille
The Print
24-06-2025
- Health
- The Print
Wegovy, the global sensation in obesity management, launched in India
Wegovy—which needs to be taken as a weekly injection—has semaglutide as an active pharmaceutical ingredient which delivers its full therapeutic strengths for complete obesity and weight management, even though low-dose semaglutide, under the brand name Rybelsus in the form of oral pills has been available in India since 2022. New Delhi: Danish pharma giant Novo Nordisk's Corporate Vice-President and Managing Director, India, Vikrant Shrotriya Tuesday announced the launch of the firm's global blockbuster fat-busting drug Wegovy in India, months after the launch of another top selling obesity drug Mounjaro in the country by US based pharma giant Eli Lilly & Company. Semaglutide helps regulate blood sugar levels, and works by binding to receptors of the gut hormone Glucagon-like peptide-1 (GLP-1). It contains a compound known as (GLP-1) receptor agonist, which mimics the naturally occurring gut hormone known to send signals of a full appetite to the brain. It is known to reduce body weight by around 15 percent after 68 weeks on average. The launch of the drug comes in India just before its patent is set to expire next year and various Indian drugmakers are set to launch its generic versions, promising to bring down the costs drastically. The largest-of-its-kind survey by the Indian Council of Medical Research (ICMR) and Madras Diabetes Research Foundation (MDRF), which was released in 2023, said that 254 million Indians, or 28.6 percent of the population, had generalised obesity. Obesity has increasingly been recognised as the root cause of various non-communicable diseases such as diabetes mellitus, cardiovascular conditions, disorders of kidney and liver and various cancers, among others. Wegovy and Mounjaro are typically indicated for those who have body mass index of 30 and above under strict expert supervision, as these drugs are also associated with various side-effects. (Edited by Zinnia Ray Chaudhuri) Also read: Fat-busting drug Mounjaro launched in India. Here's how much it will cost
Yahoo
16-05-2025
- Health
- Yahoo
Alopecia Areata: Market Trends, Regulatory Framework, Clinical Trial Analysis, Epidemiology Analysis, Market Dynamics, Competitive Landscape 2025-2035
Includes Detailed Profiles of Industry Giants Eli Lilly & Company, Pfizer, Sun Pharmaceutical Industries, Arcutis Biotherapeutics, Bristol-Myers Squibb, AbbVie, Regeneron Pharmaceuticals, and Aclaris Therapeutics Dublin, May 16, 2025 (GLOBE NEWSWIRE) -- The "Alopecia Areata Market - A Global and Regional Analysis: Focus on Drug Class and Region - Analysis and Forecast, 2025-2035" report has been added to global market for alopecia areata treatments has experienced substantial growth due to increasing awareness, advancements in medical research, and the introduction of novel therapeutic options. One of the notable examples of current treatments is JAK inhibitors like Ritlecitinib (brand name Litfulo), which received approval by the U.S. FDA for the treatment of alopecia areata in adolescents. This approval marked a significant advancement, given the earlier limited treatment options available for those suffering from this of the key drivers of the alopecia areata market is increasing prevalence of alopecia areata. Alopecia areata affects around 2% of the global population, and its prevalence has been steadily increasing. Environmental factors like stress, pollution, and lifestyle changes are contributing to this rise. The increasing incidence of autoimmune disorders overall also means more individuals are prone to developing alopecia areata. For instance, data from the American Academy of Dermatology estimates that approximately 6.8 million people in the U.S. alone have been affected by some form of traditional treatments like corticosteroids and topical immunotherapy have been somewhat effective, but the market is now being transformed by novel therapies such as JAK inhibitors, which block the pathways involved in the autoimmune attack on hair follicles. One such breakthrough is Dupixent (dupilumab), a monoclonal antibody used to treat moderate-to-severe atopic dermatitis, which has also shown promise for patients with alopecia areata. The approval of Ritlecitinib for alopecia in adolescents in 2023 is another example of how targeted therapies are creating new hope for those affected by the the market's growth, there are several challenges that hinder the wider adoption and accessibility of treatments. Advanced treatments such as biologics (e.g., Ritlecitinib and Dupixent) are often expensive, with some costing thousands of dollars per treatment cycle. This high cost of treatment limits access for many patients, particularly in developing regions where healthcare budgets are constrained. The cost barrier is significant in countries outside the U.S. and Europe, where access to biologics is more limited. The high cost of Dupixent, for example, is a point of concern for patients seeking affordable not all patients respond the same way to therapies. While JAK inhibitors have shown great promise for some individuals with alopecia areata, they may not work equally well for everyone. The variability in patient responses has led to the need for personalized treatment plans, which complicates the management of the condition and may increase healthcare addition, many regions, particularly in Africa, Asia, and Latin America, have limited access to newer treatments due to logistical, financial, and infrastructural barriers. Although global healthcare access is improving, the availability of cutting-edge treatments like JAK inhibitors remains a challenge in these underserved Segmentation Segmentation 1: by Drug Class Corticosteroids JAK (Janus Kinase) Inhibitors Others Segmentation 2: by Region North America Europe Asia-Pacific The alopecia areata market is experiencing several key emerging trends. One notable trend is the rise of personalized medicine, where treatment plans are tailored to an individual's genetic profile, disease progression, and response to therapy. Biotech companies are increasingly investing in genetic research and biomarkers to identify which patients will benefit most from specific treatments. Another trend is the growing demand for non-invasive therapies, such as topical corticosteroids, minoxidil solutions, and low-level laser therapies. These options are becoming more popular due to their reduced side effects and ease of use, offering more affordable and accessible solutions, especially in regions with limited access to biologics. As healthcare access expands globally, biologic therapies like JAK inhibitors are also gaining traction in emerging markets, with pharmaceutical companies working to improve accessibility through patient assistance programs and distribution conclusion, the Alopecia Areata (AA) market is positioned for continued growth, driven by advancements in biologic therapies, rising awareness, and increased healthcare access worldwide. Although challenges such as high treatment costs and variability in treatment response remain, the emergence of new therapies, personalized medicine, and the global expansion of access to effective treatments are poised to enhance the management of alopecia areata. The market is also benefiting from the growing emphasis on mental health and the psychological impact of hair loss, leading to more patient-centered care. As innovation continues, both large pharmaceutical companies and smaller biotech firms will drive competition and improve the quality of life for individuals living with alopecia Topics Covered1. Markets: Industry Outlook1.1 Introduction1.2 Market Trends1.3 Regulatory Framework1.4 Clinical Trial Analysis1.5 Epidemiology Analysis1.6 Market Dynamics1.6.1 Impact Analysis1.6.2 Market Drivers1.6.3 Market Challenges1.6.4 Market Opportunities2. Global Alopecia Areata Market, by Drug Class, ($Million), 2023-20352.1 Corticosteroids2.2 JAK (Janus Kinase) Inhibitors2.3 Others3. Global Alopecia Areata Market, by Region, ($Million), 2023-20353.1 North America3.1.1 Key Findings3.1.2 Market Dynamics3.1.3 Market Sizing and Forecast3.1.3.1 North America Alopecia Areata Market, by Country3.1.3.1.1 U.S.3.2 Europe3.2.1 Key Findings3.2.2 Market Dynamics3.2.3 Market Sizing and Forecast3.2.3.1 Europe Alopecia Areata Market, by Country3.2.3.1.1 Germany3.2.3.1.2 U.K.3.2.3.1.3 France3.2.3.1.4 Italy3.2.3.1.5 Spain3.3 Asia Pacific3.3.1 Key Findings3.3.2 Market Dynamics3.3.3 Market Sizing and Forecast3.3.3.1 Asia Pacific Alopecia Areata Market, by Country3.3.3.1.1 Japan4. Global Alopecia Areata Market: Competitive Landscape and Company Profiles4.1 Key Developments and Strategies4.1.1 Mergers and Acquisitions4.1.2 Synergistic Activities4.1.3 Business Expansions and Funding4.1.4 Product Launches and Approvals4.1.5 Other Activities4.2 Company Profiles4.2.1 Eli Lilly and Company4.2.1.1 Overview4.2.1.2 Top Products / Product Portfolio4.2.1.3 Target Customers/End-Users4.2.1.4 Key Personnel4.2.1.5 Analyst View4.2.2 Pfizer Inc.4.2.3 Sun Pharmaceutical Industries Ltd.4.2.4 Arcutis Biotherapeutics4.2.5 Bristol-Myers Squibb4.2.6 AbbVie4.2.7 Regeneron Pharmaceuticals4.2.8 Aclaris TherapeuticsFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
WebMD
13-05-2025
- Health
- WebMD
Why Mounjaro Tops Ozempic for Weight Loss
May 12, 2025 – Turns out, two really is better than one – at least when it comes to weight loss drugs. In the first head-to-head trial of its kind, people with obesity who took tirzepatide (sold under the brand names Mounjaro and Zepbound) lost more weight and inches from their waist than those who took semaglutide (Ozempic, Wegovy). Semaglutide is a GLP-1 agonist that boosts the hunger-suppressing hormone GLP-1. Tirzepatide is a dual agonist, targeting both GLP-1 and GIP. That means it acts on two hormone pathways, while semaglutide works on one. "We've learnt over the past 20 years or so that you can overcome the plateau effect with obesity drugs if you can add in drugs with mechanisms that are completely different," said Louis J. Aronne, MD, who led the study and is also the director of the Comprehensive Weight Control Center at Weill Cornell Medicine in New York City. "This is exactly what we see here." In the study, people taking tirzepatide lost about 20% of their body weight, while those taking semaglutide lost around 14%. They also were more likely to hit big weight loss goals – among those who lost 25% or more body weight, twice as many (32%) were on tirzepatide compared with semaglutide (16%). The findings were presented Sunday at the European Congress on Obesity 2025 in Spain, and published in The New England Journal of Medicine on the same day. The trial was sponsored by Eli Lilly & Company, the maker of tirzepatide. "They're both very good medications," said David Horner, MD, of the University of Copenhagen in Denmark, who was not involved in the study. "One is not in doubt that tirzepatide has a greater weight loss benefit from the data. We're comparing a very good drug with a very good drug." First Head-to-Head Comparison Between Two Weight Loss Drugs Both tirzepatide and semaglutide have helped people lose weight in earlier studies, but this is the first time they've been compared side by side. Of the 751 people in the study, half took tirzepatide and half took semaglutide. Both groups received weekly shots for 72 weeks, using the highest dose they could handle without strong side effects. Most people in the study were women in their mid-40s. Most were White. Everyone had struggled with their weight for many years – 16 years, on average – and had tried and failed to lose weight through diet alone. Beyond the weight loss results, tirzepatide also helped people shrink their waistlines by an extra 2 inches – by 7 inches, versus 5 inches for semaglutide. That kind of difference is "clinically meaningful and has been shown to reduce blood pressure and other metabolic parameters," Aronne said. Sure enough, people on tirzepatide saw greater improvements in key health markers like blood pressure, blood sugar, insulin, and cholesterol. "In general, the more weight someone loses, then the better the metabolic parameters will be," Aronne said. Side effects were common and were mostly mild stomach problems like nausea or diarrhea, but few people stopped taking the medicine because of them, he said – only about 6% on tirzepatide and 8% on semaglutide. Of course, the right medicine for each patient depends on a lot of things – including insurance coverage and doctor recommendations – not just which one works best in studies, said Horner.
